μg dose similar to those of a 6 μg dose. Phase III In July 2020, Sinovac began Phase III trials to evaluate efficacy and safety on 9,000 volunteer healthcare professionals in Brazil, collaborating with Butantan Institute. On 19 October, São Paulo Governor João Doria said the first results of the clinical study conducted in Brazil proved that among the vaccines being tested in the country, CoronaVac is the safest, the one with the best and most promising immunization rates. On 23 October, São Paulo increased the number of volunteers in the trial to 13,000. Brazil briefly paused the trials on 10 November after the suicide of a volunteer before resuming them the next day. The suicide was unrelated to the vaccine trial. In August, a trial was started in Chile run by Pontifical Catholic University of Chile which was expected to include 3,000 volunteers between the ages of 18 and 65. In August, Sinovac began trials in Indonesia with Bio Farma in Bandung involving 1,620 volunteers. In September, Turkey began trials with 13,000 volunteers on a two-dose 14-day interval. The monitoring process took place at 25 centers in 12 cities across the country. In October, Sinovac began trials in China involving 1,040 volunteers. In April 2021, Sinovac began Phase II/III trials for the elderly aged 60–80 in the Philippines involving 352 volunteers. Children and adolescents trials In September 2020, Sinovac began Phase I–II trials in China on children and adolescents ages 3–17. In May 2021, Sinovac began Phase IIb trials in China with 500 participants for children and adolescents 3–17 years old. In June 2021, it was announced that the vaccine was safe and immunogenic in this age group. In July, Sinovac began Phase III trials in Chile with 14,000 participants for children and adolescents and expand from 6 months to 17 years old. Results of Phase III trials Peer-reviewed Phase III results from Turkey showed an efficacy of . The final efficacy rate was based on 41 infections, 32 of which had received a placebo. The vaccine prevented hospitalization and severe illness in 100% of cases, with all six people who were hospitalized in the placebo group. The final results were based on 10,218 participants in the trials. Phase III results from Brazil submitted to Lancet showed 50.7% efficacy at preventing symptomatic infections, 83.7% effective in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with